New Non-Opioid Drug Approved as German Firms Grapple with Soaring Absenteeism Costs
11.06.2026 - 02:22:52 | boerse-global.de
A new non-opioid medication for chronic lower back pain received regulatory approval in Germany in early June 2026, offering a potential lifeline for the country's strained manufacturing sector. Clinical trials involving more than 1,200 patients showed a significant reduction in pain, and the drug is scheduled for market launch in September. The development comes as German companies face mounting financial pressure from skyrocketing sick-leave rates, particularly in physically demanding jobs.
Absenteeism in production has climbed sharply. The DAK health insurance fund reported a 38-percent increase in sick days during 2024 compared with the prior year. Every day a worker is absent in a factory costs an estimated 300 to 600 euros, according to industry experts. At the Tesla Gigafactory site, estimates land at the higher end of that range. A simple calculation: 50 employees averaging 20 sick days each per year can generate costs in the low-to-mid six figures — or higher.
Sustainable workplace health management starts with knowing where the risks are. A free Risk Assessment Toolkit provides 41 ready-to-use checklists and templates to help you identify hazards before they lead to injury and lost workdays. Download the free Risk Assessment Toolkit
Some employers have responded with restrictive measures, including suspending continued wage payments or challenging medical certificates. Health experts instead recommend sustainable workplace health management and supplementary business insurance policies as a more effective long-term strategy.
The burden is also visible in Germany’s public health insurance system. The Scientific Institute of the AOK (WIdO) published its Heilmittel-Report on June 9, 2026, showing that statutory health funds spent 13.3 billion euros on remedial therapies in 2024 — double the figure from a decade earlier. Projections for 2025 point to a further increase to 14.7 billion euros, a rise of 10.4 percent. First-quarter data for 2026 confirm the upward trend, with an 8.7-percent increase.
Nearly 70 percent of these expenditures go to physiotherapy. A particularly contentious issue involves so-called blank prescriptions — open prescriptions where the therapist decides the treatment scope. For shoulder complaints, a blank prescription averages 714 euros compared with only 214 euros for a standard doctor’s prescription. AOK leadership is calling for stronger scientific evidence before expanding such models. Critics also highlight Germany’s lag behind other EU countries in professionalizing therapist training at the university level.
Industry is responding with engineering solutions. Modern handling equipment — manipulators capable of lifting up to 800 kilograms and lifting axes for loads up to 1,200 kilograms — is becoming standard in many factories. According to Zeilhofer Handhabungstechnik, a specialist firm, such investments pay for themselves within 12 to 24 months purely through reduced illness-related downtime.
Engineering solutions reduce physical strain, but comprehensive health and safety compliance requires documented policies across all risk areas. A free Health & Safety Toolkit gives you risk assessments, checklists, and toolbox talks covering UK regulations from fire safety to manual handling. Download the free Health & Safety Toolkit
The policy arena has also moved. At the end of May 2026, the German cabinet classified Parkinson’s disease as an occupational illness under certain conditions. The change primarily affects workers in agriculture, forestry, and horticulture, who now qualify for pension and rehabilitation benefits if they develop the disease due to work-related exposure.
Private disability insurance, however, remains a weak link. The BU-Leistungspraxisstudie 2026 by Franke & Bornberg found that while roughly 80 percent of disability claims are accepted, the time to settlement increased to an average of 201 days in 2024. Across all industries, mental health conditions account for more than 28 percent of claims, but in production sectors, physical wear-and-tear remains the dominant reason for leaving the workforce prematurely.
